A single-arm Phase II trial was conducted, in which patients with mRCC were intradermally vaccinated with a minimum of three whole-cell vaccines containing 0.7 – 1.3 x 10^7 irradiated autologous tumor cells (ATC), admixed with 1 mg CpG-B and 100 μg GM-CSF, followed by bi-weekly subcutaneous (SC) injections with 8 mg CpG-B and SC injections with 6 MU IFNα three times per week. The gene discussed is IFNA2; the disease is neoplasm.